Urinary Incontinence

PSB-10211 is a P2X2 receptor antagonist with an IC₅₀ of 0.086 μM against rat P2X2 receptors. PSB-10211 inhibits ATP-mediated currents of rat P2X2 receptors expressed in Xenopus oocytes. PSB-10211 can be used in studies related to pain and urinary incontinence.

α1A Adrenoceptor agonist-1 (compound 13) is an α₁A adrenoceptor (α₁A adrenoceptor) agonist with an EC₅₀ of 385 nM for α1A. α1A Adrenoceptor agonist-1 exhibits in vitro functional agonistic activity targeting adrenoceptors. α1A Adrenoceptor agonist-1 can be used for the research of stress urinary incontinence.

RCC-36 hydrochloride is an L-type calcium channel inhibitor and competitive muscarinic receptor antagonist. RCC-36 hydrochloride inhibits L-type calcium currents in voltage- and concentration-dependent fashion with no effect on cardiac K⁺ currents. RCC-36 hydrochloride suppresses maximum acetylcholine-induced contractile responses, inhibits detrusor muscle contractions induced by potassium chloride, calcium chloride, and electric field stimulation, including atropine-resistant contractions. RCC-36 hydrochloride can be used for the research of urinary frequency, urinary incontinence, and bladder overactivity.

Phenamacide hydrochloride is an anti-spasmodic agent that can be used for the study of urinary incontinence.

Adosupine is a tricyclic compound that affects detrusor hyperreflexia via central nervous system sites. Adosupine can be used in studies related to detrusor hyperreflexia and urinary incontinence.